CorMedix Inc.

Case Overview
Status: | Status: Investigating |
Company Name: | Company Name: CorMedix Inc. |
Ticker: | Ticker: CRMD |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against CorMedix Inc. (“CorMedix” or the “Company”) (NASDAQ:CRMD). The investigation concerns whether CorMedix and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
On March 25, 2025, CorMedix issued a “business update” including net revenue guidance for the first half of 2025 of $50-$60 million (the “Guidance”) that fell below consensus analyst estimates. As CorMedix further revealed, the Guidance shortfall was driven by its “Large Dialysis Operator” customer, which had previously informed CorMedix of “operational resource constraints” that would delay its implementation of CorMedix’s DefenCath product. In response to this Guidance news, the price of CorMedix shares fell by $2.40 per share, from $11.09 per share on March 24, 2025, to close at $8.69 on March 25, 2025.
On March 25, 2025, CorMedix issued a “business update” including net revenue guidance for the first half of 2025 of $50-$60 million (the “Guidance”) that fell below consensus analyst estimates. As CorMedix further revealed, the Guidance shortfall was driven by its “Large Dialysis Operator” customer, which had previously informed CorMedix of “operational resource constraints” that would delay its implementation of CorMedix’s DefenCath product. In response to this Guidance news, the price of CorMedix shares fell by $2.40 per share, from $11.09 per share on March 24, 2025, to close at $8.69 on March 25, 2025.